Somatostatin and CXCR4 Expression Patterns in Adenocarcinoma and Squamous Cell Carcinoma of the Lung Relative to Small Cell Lung Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2018 Aug 5

PMID 30076481

Citations 12

Authors

Claudia Stumpf

Daniel Kaemmerer

Elisa Neubauer

Jorg Sanger

Stefan Schulz

Amelie Lupp

Affiliations

Soon will be listed here.

Abstract

Purpose: Lung cancer is highly prevalent and has an especially poor prognosis. Thus, new diagnostic and therapeutic targets are necessary. Two potential targets are somatostatin receptors (SST), which are overexpressed in well-differentiated neuroendocrine neoplasms, and the chemokine receptor CXCR4, which is present mainly in highly proliferative and advanced tumours. Although their expression is relatively well characterized in small cell lung cancer (SCLC), in non-small cell lung cancer (NSCLC), data on SST and CXCR4 expression are scarce and contradictory.

Methods: We comparatively evaluated 83 tumour samples from a total of 57 lung cancer patients, of which 22 had adenocarcinoma (ADC), 21 had squamous cell carcinoma (SQC), and 15 had SCLC. Samples were evaluated for SST and CXCR4 expression using immunohistochemistry with well-characterized rabbit monoclonal antibodies.

Results: In the samples investigated, the most prominently expressed receptors were CXCR4 and SST5. Specifically, CXCR4 was detected with high expression intensity in more than 60% of ADC samples, about 90% of SQC, and 100% of SCLC. SST5 was present in about 75% of ADC and SQC samples and in more than 90% of SCLC. Although not noticeably expressed in ADC and SQC samples, SST2 was detected in 50% of SCLC cases, with a subset of patients displaying exceptionally high expression. The comparison of the three tumour entities revealed that SCLC samples had higher SST2, SST5, and CXCR4 expression, but lower SST3 and SST1 relative to ADC or SQC samples.

Conclusion: CXCR4 may be a promising target for diagnostics and therapy in both SCLC and NSCLC.

Citing Articles

GLI1-Altered Mesenchymal Tumor with ACTB Fusion and Somatostatin Receptor 2A (SSTR2A) Immunopositivity.

Grove J, Geisler D, Naous R Cureus. 2024; 16(11):e74325.

PMID: 39720383 PMC: 11666418. DOI: 10.7759/cureus.74325.

The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review.

Kasprzak A, Geltz A Biomedicines. 2024; 12(3).

PMID: 38540191 PMC: 10968376. DOI: 10.3390/biomedicines12030578.

Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Czajkowski M, Kaemmerer D, Sanger J, Sauter G, Wirtz R, Schulz S BMC Cancer. 2022; 22(1):740.

PMID: 35799158 PMC: 9261050. DOI: 10.1186/s12885-022-09839-z.

The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.

Qiu L, Xu Y, Xu H, Yu B BMC Cancer. 2022; 22(1):681.

PMID: 35729596 PMC: 9210617. DOI: 10.1186/s12885-022-09756-1.

CircPTN promotes angiogenesis via the MiR-595/LYRM5 signaling pathway in non-small cell lung cancer.

Guo S, Mao Z, Zhang G, Xu B, He X Transl Cancer Res. 2022; 11(3):519-529.

PMID: 35402183 PMC: 8990826. DOI: 10.21037/tcr-22-195.

References

Singh S, Han L, Murali R, Solis L, Roth J, Ji L . SSTR2-based reporters for assessing gene transfer into non-small cell lung cancer: evaluation using an intrathoracic mouse model. Hum Gene Ther. 2010; 22(1):55-64. PMC: 3025187. DOI: 10.1089/hum.2010.109. View

Lupp A, Nagel F, Schulz S . Reevaluation of sst₁ somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7. Regul Pept. 2013; 183:1-6. DOI: 10.1016/j.regpep.2013.02.001. View

Wagner P, Hyjek E, Vazquez M, Meherally D, Liu Y, Chadwick P . CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 2009; 137(3):615-21. DOI: 10.1016/j.jtcvs.2008.07.039. View

Lambertini C, Barzaghi-Rinaudo P, DAmato L, Schulz S, Nuciforo P, Schmid H . Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regul Pept. 2013; 187:35-41. DOI: 10.1016/j.regpep.2013.10.007. View

Reckamp K, Figlin R, Burdick M, Dubinett S, Elashoff R, Strieter R . CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009; 9:213. PMC: 2708193. DOI: 10.1186/1471-2407-9-213. View

Mehta S, de Reuver P, Gill P, Andrici J, Durso L, Mittal A . Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. Medicine (Baltimore). 2015; 94(40):e1281. PMC: 4616753. DOI: 10.1097/MD.0000000000001281. View

Lapa C, Luckerath K, Rudelius M, Schmid J, Schoene A, Schirbel A . [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience. Oncotarget. 2016; 7(8):9288-95. PMC: 4891040. DOI: 10.18632/oncotarget.7063. View

Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C . European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?. Ann Oncol. 2015; 26(4):779-786. DOI: 10.1093/annonc/mdv001. View

Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F . International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014; 84(1):13-22. DOI: 10.1016/j.lungcan.2014.01.009. View

10.

Fischer T, Nagel F, Jacobs S, Stumm R, Schulz S . Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One. 2009; 3(12):e4069. PMC: 2605258. DOI: 10.1371/journal.pone.0004069. View

11.

Walker R, Deppen S, Smith G, Shi C, Lehman J, Clanton J . 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. PLoS One. 2017; 12(2):e0171301. PMC: 5300187. DOI: 10.1371/journal.pone.0171301. View

12.

Callison Jr J, Walker R, Massion P . Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics. J Lung Cancer. 2015; 10(2):69-76. PMC: 4319675. DOI: 10.6058/jlc.2011.10.2.69. View

13.

Reck M, Heigener D, Mok T, Soria J, Rabe K . Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382(9893):709-19. DOI: 10.1016/S0140-6736(13)61502-0. View

14.

Kaemmerer D, Specht E, Sanger J, Wirtz R, Sayeg M, Schulz S . Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab. 2014; 100(3):831-40. DOI: 10.1210/jc.2014-2699. View

15.

Spano J, Andre F, Morat L, Sabatier L, Besse B, Combadiere C . Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004; 15(4):613-7. DOI: 10.1093/annonc/mdh136. View

16.

Corleto V, Falconi M, Panzuto F, Milione M, De Luca O, Perri P . Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology. 2008; 89(2):223-30. DOI: 10.1159/000167796. View

17.

Na I, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E . Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol. 2008; 39(12):1751-5. DOI: 10.1016/j.humpath.2008.04.017. View

18.

Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J . Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial. Lung Cancer. 2004; 45(3):365-71. DOI: 10.1016/j.lungcan.2004.02.020. View

19.

Kaemmerer D, Trager T, Hoffmeister M, Sipos B, Hommann M, Sanger J . Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget. 2015; 6(29):27566-79. PMC: 4695009. DOI: 10.18632/oncotarget.4491. View

20.

Otsuka S, Klimowicz A, Kopciuk K, Petrillo S, Konno M, Hao D . CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol. 2011; 6(7):1169-78. DOI: 10.1097/JTO.0b013e3182199a99. View